4      0


ILLUMINATE-B, a Phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1)



Credits: None available.

Description

Participants will be able to evaluate the impact of lumasiran, a RNAi therapuetic in young children with primary hyperoxaluria type 1 (PH1)- a rare genetic kidney disorder

Speaker(s):

Credits

Credits: None available.

You must be logged in and own this session in order to post comments.